Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 3:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 386 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Kidney Transplant Symptoms Clear all
Completed Not applicable Interventional

Explore Transplant at Home: Improving Low-Income ESRD Patients' Transplant Knowledge

NCT02268682
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Patient-Guided, Educator-Guided
Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 74 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Oct 2, 2026, 3:22 PM EDT
Terminated Not applicable Interventional

The Effect of Oxygen on Healing an Artery From the "Injury" of Surgery

NCT00863603
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
oxygen
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 25, 2012 · Synced Oct 2, 2026, 3:22 PM EDT
Completed Phase 4 Interventional Results available

Novartis Everolimus Transition

NCT02096107
View directory record Official record
Conditions
Graft Dysfunction, Interstitial Fibrosis
Interventions
Everolimus, Standard of Care
Drug · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 2, 2026, 3:22 PM EDT
Suspended No phase listed Observational

Role of Pancreatic Exocrine Secretion in Weight Gain After Pancreas Transplantation

NCT04690738
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency, Weight Gain
Interventions
Fecal Elastase Concentration
Diagnostic Test
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 2, 2026, 3:22 PM EDT
Enrolling by invitation Not applicable Interventional

Xeltis Hemodialysis Access Graft (aXess) US Study

NCT06494631
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Xeltis Hemodialysis Access (aXess) graft
Device
Lead sponsor
Xeltis
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
7
States / cities
Phoenix, Arizona • Tuscon, Arizona • Sarasota, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 2, 2026, 3:22 PM EDT
Terminated Phase 2Phase 3 Interventional

A Study to Evaluate the Effect of ASP8597 in Adult Kidney Transplant Patients

NCT01442337
View directory record Official record
Conditions
Kidney Transplantation
Interventions
ASP8597, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
19
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2014 · Synced Oct 2, 2026, 3:22 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients

NCT03036930
View directory record Official record
Conditions
Human Papillomavirus Infection, Human Papillomavirus-Related Carcinoma
Interventions
Biospecimen Collection, HPV Self-Collection, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine
Procedure · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 49 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 2, 2026, 3:22 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients

NCT01544491
View directory record Official record
Conditions
Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant
Interventions
RAD001, MMF
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 18 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Ann Arbor, Michigan • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Oct 2, 2026, 3:22 PM EDT
Completed Not applicable Interventional

Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation

NCT00080873
View directory record Official record
Conditions
Kidney Cancer, Leukemia, Lymphoma, Neuroblastoma, Oral Complications, Sarcoma
Interventions
Traumeel S, Placebo
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 25 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
37
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Oct 2, 2026, 3:22 PM EDT
Completed Phase 4 Interventional Results available

Small Bowel Capsule Endoscopy Findings in Patients Receiving Cellcept®

NCT00652834
View directory record Official record
Conditions
Gastrointestinal Lesions, Signs and Symptoms, Digestive
Interventions
Small bowel capsule endoscopy (SBCE), myfortic
Procedure · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2016 · Synced Oct 2, 2026, 3:22 PM EDT
Completed No phase listed Observational Results available

BK Virus Infection (Viremia) Natural History in Renal Transplant Recipients

NCT01782209
View directory record Official record
Conditions
BK Virus (BKV) Viremia
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 2, 2026, 3:22 PM EDT
Terminated Phase 3 Interventional Results available

Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy

NCT04741074
View directory record Official record
Conditions
CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese, Obesity, Severe Obesity
Interventions
Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution, Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution
Drug
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Danville, Pennsylvania • Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 2, 2026, 3:22 PM EDT
Active, not recruiting Phase 4 Interventional

Angiotensin 2 for AKI After OLT

NCT04592744
View directory record Official record
Conditions
Cirrhosis, Liver, End Stage Liver DIsease, Acute Kidney Injury, Liver Transplant; Complications
Interventions
Angiotensin II, Norepinephrine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 2, 2026, 3:22 PM EDT
Completed Phase 2 Interventional

Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant

NCT00357084
View directory record Official record
Conditions
Cancer
Interventions
methotrexate, methylprednisolone, prednisone
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 14, 2010 · Synced Oct 2, 2026, 3:22 PM EDT
Completed Phase 4 Interventional Results available

Angiotensin II Blockade for Chronic Allograft Nephropathy

NCT00067990
View directory record Official record
Conditions
Kidney Disease, Proteinuria
Interventions
Losartan 100mg, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Oct 2, 2026, 3:22 PM EDT
Completed Phase 2 Interventional Results available

Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection

NCT00801632
View directory record Official record
Conditions
Kidney Transplantation, Kidney Failure, Chronic
Interventions
Kidney Transplantation, Bone marrow transplantation, MEDI-507, cyclophosphamide, rituximab, Tacrolimus, corticosteroids, thymic irradiation
Procedure · Biological · Drug + 1 more
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Oct 2, 2026, 3:22 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Dental Intervention Plan for Chronic Kidney Disease Patients Awaiting or With Kidney Transplant

NCT04020458
View directory record Official record
Conditions
Chronic Kidney Disease, Chronic Periodontitis, Generalized, Moderate
Interventions
dental intervention
Procedure
Lead sponsor
Augusta University
Other
Eligibility
21 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 2, 2026, 3:22 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Direct to Patient Minimal Risk Biospecimen and Data Collection Research

NCT07128966
View directory record Official record
Conditions
Healthy, Lupus, Celiac, Kidney Disease, Chronic, Dermatologic
Interventions
Observation
Other
Lead sponsor
Joined Bio
Industry
Eligibility
18 Years to 90 Years
Enrollment
100,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2036
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 2, 2026, 3:22 PM EDT
Terminated Phase 2 Interventional Results available

The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients

NCT03960554
View directory record Official record
Conditions
Osteoporosis, Renal Osteodystrophy, Kidney Transplant; Complications
Interventions
Denosumab Inj 60 mg/ml, Placebo
Drug · Other
Lead sponsor
Thomas Nickolas, MD MS
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Chicago, Illinois • Evanston, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Oct 2, 2026, 3:22 PM EDT
Completed No phase listed Observational

Long Term Use of Valganciclovir for Prophylaxis of CMV Disease in Kidney and Pancreas Transplant Patients

NCT00225394
View directory record Official record
Conditions
CMV Disease, Viral Resistance, Rejection, Death
Interventions
Not listed
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
4
States / cities
Boston, Massachusetts • Burlington, Massachusetts • Worcester, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2005 · Synced Oct 2, 2026, 3:22 PM EDT
Completed Not applicable Interventional

Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders

NCT01758042
View directory record Official record
Conditions
Chronic Kidney Disease, Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL), Hodgkin Disease, Multiple Myeloma, Myelodysplastic Syndrome (MDS), Aplastic Anemia, AL Amyloidosis, Diamond Blackfan Anemia, Myelofibrosis, Myeloproliferative Disease, Sickle Cell Anemia, Autoimmune Diseases, Thalassemia
Interventions
Haploidentical Bone Marrow/Kidney
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 2, 2026, 3:22 PM EDT
Completed Phase 4 Interventional

Pilot Study Evaluating Doxercalciferol Replacement Therapy in Kidney Transplant Recipients

NCT00889629
View directory record Official record
Conditions
Chronic Kidney Disease, Kidney Transplantation
Interventions
Doxercalciferol, placebo, 25-OH Vitamin D3
Drug
Lead sponsor
Mariana Markell
Other
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 2, 2026, 3:22 PM EDT
Not listed No phase listed Observational

Predicting Mortality in Kidney Transplant Recipients

NCT06531967
View directory record Official record
Conditions
Death
Interventions
No intervention
Other
Lead sponsor
Paris Translational Research Center for Organ Transplantation
Other
Eligibility
18 Years to 100 Years
Enrollment
13,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2024
U.S. locations
3
States / cities
Phoenix, Arizona • San Francisco, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 2, 2026, 3:22 PM EDT
Active, not recruiting Phase 2 Interventional

ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function

NCT05907096
View directory record Official record
Conditions
Delayed Graft Function
Interventions
ARGX-117, Placebo
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years to 70 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
8
States / cities
Los Angeles, California • Tampa, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 2, 2026, 3:22 PM EDT